12/4
08:10 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) was given a new $11.00 price target on by analysts at UBS Group AG.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) was given a new $11.00 price target on by analysts at UBS Group AG.
12/4
07:04 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "buy" rating.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "buy" rating.
12/4
07:03 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) was given a new $11.00 price target on by analysts at The Goldman Sachs Group, Inc..
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) was given a new $11.00 price target on by analysts at The Goldman Sachs Group, Inc..
12/2
03:46 pm
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
02:19 pm
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
06:38 am
tsha
Is Taysha Gene Therapies Inc. (TSHA) One of the Must-Buy Penny Stocks to Buy Now? [Yahoo! Finance]
Low
Report
Is Taysha Gene Therapies Inc. (TSHA) One of the Must-Buy Penny Stocks to Buy Now? [Yahoo! Finance]
11/14
09:14 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
11/7
09:50 pm
tsha
Citizens Lifts Price Target for Taysha Gene Therapies (TSHA) [Yahoo! Finance]
Medium
Report
Citizens Lifts Price Target for Taysha Gene Therapies (TSHA) [Yahoo! Finance]
11/5
08:44 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) was given a new $8.00 price target on by analysts at JMP Securities.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) was given a new $8.00 price target on by analysts at JMP Securities.
11/5
08:07 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
11/5
08:07 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its price target raised by analysts at Citizens Jmp from $6.00 to $8.00. They now have a "market outperform" rating on the stock.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its price target raised by analysts at Citizens Jmp from $6.00 to $8.00. They now have a "market outperform" rating on the stock.
11/5
07:19 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
11/4
07:00 am
tsha
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Low
Report
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/30
12:31 pm
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/28
08:00 am
tsha
Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4
Low
Report
Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4
10/26
06:47 am
tsha
Taysha Gene Therapies Regains Full Global Rights to Lead Rett Syndrome Program TSHA-102 [Yahoo! Finance]
Low
Report
Taysha Gene Therapies Regains Full Global Rights to Lead Rett Syndrome Program TSHA-102 [Yahoo! Finance]
10/21
08:03 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating and a $13.00 price target on the stock.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating and a $13.00 price target on the stock.
10/17
08:47 pm
tsha
How Regaining Full Rights to Rett Syndrome Gene Therapy Has Changed Taysha (TSHA)'s Investment Story [Yahoo! Finance]
Medium
Report
How Regaining Full Rights to Rett Syndrome Gene Therapy Has Changed Taysha (TSHA)'s Investment Story [Yahoo! Finance]
10/17
08:12 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
10/17
08:12 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
10/16
04:01 pm
tsha
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
Medium
Report
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
10/9
08:45 am
tsha
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting [Yahoo! Finance]
Low
Report
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting [Yahoo! Finance]
10/9
08:00 am
tsha
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting
Low
Report
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting
10/6
10:08 am
tsha
Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential [Seeking Alpha]
Medium
Report
Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential [Seeking Alpha]
10/5
05:18 am
tsha
How Recent Developments Are Rewriting the Story for Taysha Gene Therapies [Yahoo! Finance]
Medium
Report
How Recent Developments Are Rewriting the Story for Taysha Gene Therapies [Yahoo! Finance]